Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease

Mary Grace Hren; Sophie Guenin; Saakshi Khattri

doi:10.1016/j.jaad.2024.03.007

Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease

J Am Acad Dermatol. 2024 Jul;91(1):138-140. doi: 10.1016/j.jaad.2024.03.007. Epub 2024 Mar 15.

Authors

Mary Grace Hren¹, Sophie Guenin², Saakshi Khattri³

Affiliations

¹ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; Renaissance School of Medicine, Stony Brook University, Stony Brook, New York.
² Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; New York Medical College, Valhalla, New York.
³ Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: saakshi.khattri@mountsinai.org.

PMID: 38494153
DOI: 10.1016/j.jaad.2024.03.007

No abstract available

Keywords: atopic dermatitis; autoimmune disease; biologic therapy; dual biologic therapy; dupilumab; inflammatory bowel disease; inflammatory skin disease; psoriasis; psoriatic arthritis.

Publication types

Letter

MeSH terms

Adult
Arthritis, Psoriatic* / complications
Arthritis, Psoriatic* / drug therapy
Biological Therapy / methods
Dermatitis, Atopic* / complications
Dermatitis, Atopic* / drug therapy
Drug Therapy, Combination
Female
Humans
Inflammatory Bowel Diseases* / complications
Inflammatory Bowel Diseases* / drug therapy
Male
Middle Aged
Psoriasis* / complications
Psoriasis* / drug therapy
Psoriasis* / immunology
Th17 Cells* / immunology
Th2 Cells* / immunology
Treatment Outcome